SE0203778D0 - A new oral immediated release dosage form - Google Patents

A new oral immediated release dosage form

Info

Publication number
SE0203778D0
SE0203778D0 SE0203778A SE0203778A SE0203778D0 SE 0203778 D0 SE0203778 D0 SE 0203778D0 SE 0203778 A SE0203778 A SE 0203778A SE 0203778 A SE0203778 A SE 0203778A SE 0203778 D0 SE0203778 D0 SE 0203778D0
Authority
SE
Sweden
Prior art keywords
dosage form
immediate release
release dosage
oral immediate
new oral
Prior art date
Application number
SE0203778A
Other languages
English (en)
Inventor
Patrik Eriksson
Barbro Johansson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203778A priority Critical patent/SE0203778D0/sv
Publication of SE0203778D0 publication Critical patent/SE0203778D0/sv
Priority to ARP030104473A priority patent/AR042297A1/es
Priority to TW092134411A priority patent/TW200502002A/zh
Priority to EP03776159A priority patent/EP1572158A1/en
Priority to PCT/SE2003/001910 priority patent/WO2004052342A1/en
Priority to AU2003283937A priority patent/AU2003283937A1/en
Priority to US10/537,858 priority patent/US20060034911A1/en
Priority to JP2004558963A priority patent/JP2006510665A/ja
Priority to UY28111A priority patent/UY28111A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0203778A 2002-12-09 2002-12-09 A new oral immediated release dosage form SE0203778D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0203778A SE0203778D0 (sv) 2002-12-09 2002-12-09 A new oral immediated release dosage form
ARP030104473A AR042297A1 (es) 2002-12-09 2003-12-04 Forma de dosificacion oral de liberacion inmediata
TW092134411A TW200502002A (en) 2002-12-09 2003-12-05 A new oral immediated release dosage form
EP03776159A EP1572158A1 (en) 2002-12-09 2003-12-08 A new oral immediated release dosage form
PCT/SE2003/001910 WO2004052342A1 (en) 2002-12-09 2003-12-08 A new oral immediated release dosage form
AU2003283937A AU2003283937A1 (en) 2002-12-09 2003-12-08 A new oral immediated release dosage form
US10/537,858 US20060034911A1 (en) 2002-12-09 2003-12-08 New oral immediated release dosage form
JP2004558963A JP2006510665A (ja) 2002-12-09 2003-12-08 新規な経口即時放出型投与剤形
UY28111A UY28111A1 (es) 2002-12-09 2003-12-09 Nueva forma de dosificación oral de liberación inmediata

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203778A SE0203778D0 (sv) 2002-12-09 2002-12-09 A new oral immediated release dosage form

Publications (1)

Publication Number Publication Date
SE0203778D0 true SE0203778D0 (sv) 2002-12-09

Family

ID=20289929

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203778A SE0203778D0 (sv) 2002-12-09 2002-12-09 A new oral immediated release dosage form

Country Status (9)

Country Link
US (1) US20060034911A1 (sv)
EP (1) EP1572158A1 (sv)
JP (1) JP2006510665A (sv)
AR (1) AR042297A1 (sv)
AU (1) AU2003283937A1 (sv)
SE (1) SE0203778D0 (sv)
TW (1) TW200502002A (sv)
UY (1) UY28111A1 (sv)
WO (1) WO2004052342A1 (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含***并[4,5-d]嘧啶衍生物之組合物
BR112020004045A2 (pt) * 2017-08-30 2020-09-01 Prilenia Neurotherapeutics Ltd. formas de dosagem de elevada concentração de pridopidina
KR102007499B1 (ko) * 2017-09-11 2019-08-05 에이비온 주식회사 트리아졸로피라진계 화합물, 결합제 및 붕해제를 포함하는 속방형 캡슐제 조성물
TWI795462B (zh) 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
KR102659095B1 (ko) * 2021-01-08 2024-04-19 에이비온 주식회사 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232003T2 (de) * 1991-09-18 2002-04-25 Glaxo Group Ltd Benzanilidderivate als 5-HT1D-Antagonisten
JPH10114655A (ja) * 1996-10-09 1998-05-06 Kyowa Hakko Kogyo Co Ltd 固形製剤
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
ATE431136T1 (de) * 2000-09-22 2009-05-15 Dainippon Sumitomo Pharma Co Orale zubereitungen mit vorteilhaften zerfallseigenschaften
DE60103299T2 (de) * 2000-10-30 2005-05-12 Lupin Ltd., Mumbai Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe

Also Published As

Publication number Publication date
EP1572158A1 (en) 2005-09-14
UY28111A1 (es) 2004-07-30
AU2003283937A1 (en) 2004-06-30
WO2004052342A1 (en) 2004-06-24
JP2006510665A (ja) 2006-03-30
US20060034911A1 (en) 2006-02-16
TW200502002A (en) 2005-01-16
AR042297A1 (es) 2005-06-15

Similar Documents

Publication Publication Date Title
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
ATE414519T1 (de) Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
ATE390133T1 (de) Gabapentinanaloga für schlafstörungen
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JO2371B1 (en) 4-phenyl-pyridine derivatives
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
RS50876B (sr) Upotreba flibanserina u lečenju seksualnih poremećaja
MY133238A (en) Monoamine reuptake inhibitors for treatment for cns disorders
UA83233C2 (ru) Замещенный 2-аминотетралин для лечения депрессии
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
SE0102440D0 (sv) New compound
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
HK1075894A1 (en) Prucalopride-n-oxide
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
SE0203778D0 (sv) A new oral immediated release dosage form
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
SE0102887D0 (sv) New formulation
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
MY133438A (en) Morpholinobenzamide salts
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
SE0102886D0 (sv) New formulation
SE0102888D0 (sv) New formulation
HUP0002905A2 (hu) 2-{4-[4-(4,5-Diklór-2-metilimidazol-1-il)butil]1-1piperazinil}-5-fluorpirimidin, előállítása és gyógyászati alkalmazása